In 157 patients with resected stage IIIB–IV melanoma, adding the mRNA neoantigen therapy intismeran to pembrolizumab kept improving recurrence-free survival at 5-year descriptive follow-up (HR 0.510; 95% CI 0.294–0.887); overall survival HR 0.471 was not significant.
RCTn = 157
Khattak et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study